Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
Status:
Recruiting
Trial end date:
2021-11-17
Target enrollment:
Participant gender:
Summary
This is a phase Ib, multi-center, open label study evaluating the safety and efficacy of
CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC
who have progressed after EGFR TKI treatment.